| Bioactivity | Silibinin (Silibinin A), an effective anti-cancer and chemopreventive agent, has been shown to exert multiple effects on cancer cells, including inhibition of both cell proliferation and migration. | ||||||||||||
| Invitro | Silibinin (Silybin) significantly induced the expression of the non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) in both p53 wild-type and p53-null cancer cell lines[1].Silibinin (Silybin) induced cell death in human breast cancer cell lines MCF7 and MDA-MB-231[2].Silibinin (Silybin) treatment resulted in a dose- and time-dependent inhibition of HCC cell viability[3].Silibinin (Silybin) treatment decreased the expression of the Notch1 intracellular domain (NICD), RBP-Jκ, and Hes1 proteins, upregulated the apoptosis pathway-related protein Bax, and downregulated Bcl2, survivin, and cyclin D1[3]. | ||||||||||||
| Name | Silibinin | ||||||||||||
| CAS | 22888-70-6 | ||||||||||||
| Formula | C25H22O10 | ||||||||||||
| Molar Mass | 482.44 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|